DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Keppra XR (Levetiracetam) - Summary



KEPPRA XR is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration.

KEPPRA XR™ is indicated as adjunctive therapy in the treatment of partial onset seizures in patients ≥16 years of age with epilepsy.

See all Keppra XR indications & dosage >>


Media Articles Related to Keppra XR (Levetiracetam)

New method identifies brain regions most likely to cause epilepsy seizures
Source: Epilepsy News From Medical News Today [2017.08.17]
Mathematical approach could pinpoint which brain tissue should be removed during surgical treatment.

Pot Compound Alters Levels of Seizure Drug in Epilepsy Patients
Source: MedicineNet Seizure Specialty [2017.08.14]
Title: Pot Compound Alters Levels of Seizure Drug in Epilepsy Patients
Category: Health News
Created: 8/11/2017 12:00:00 AM
Last Editorial Review: 8/14/2017 12:00:00 AM

Number of Americans With Epilepsy at Record Level
Source: MedicineNet Brain Tumor Specialty [2017.08.11]
Title: Number of Americans With Epilepsy at Record Level
Category: Health News
Created: 8/10/2017 12:00:00 AM
Last Editorial Review: 8/11/2017 12:00:00 AM

Genetic testing helps detect cause of early life epilepsy
Source: Epilepsy News From Medical News Today [2017.08.02]
A study published in JAMA Pediatrics supports the use of genetic testing, especially with sequencing, as first-line diagnostic method for young children with seizures.

Genetic Testing Can Help Pinpoint Epilepsy Earlier
Source: MedicineNet Seizure Specialty [2017.08.01]
Title: Genetic Testing Can Help Pinpoint Epilepsy Earlier
Category: Health News
Created: 7/31/2017 12:00:00 AM
Last Editorial Review: 8/1/2017 12:00:00 AM

more news >>

Published Studies Related to Keppra XR (Levetiracetam)

Levetiracetam in the treatment of alcohol dependence: toward the end of the story? [2012]
that levetiracetam may be efficient in alcohol-related disorder... CONCLUSIONS: By conducting a state-of-the-art randomized-controlled clinical

A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. [2012]
population of very heavy drinkers... CONCLUSIONS: This multisite clinical trial showed no efficacy for levetiracetam

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs. [2012]
BACKGROUND: Status epilepticus (SE) and acute repetitive seizures (ARS) are common canine neurologic emergencies...

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. [2011.07]
BACKGROUND: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease... CONCLUSIONS: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. (c) 2011 Movement Disorder Society. Copyright (c) 2011 Movement Disorder Society.

The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2011.07]
Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A. This could have an impact on signaling in the nociceptive system, and a pilot study indicated relief of neuropathic pain with levetiracetam. OBJECTIVES: The aim of this study was to test the analgesic effect of levetiracetam in painful polyneuropathy... CONCLUSION: This study indicates that the anticonvulsant levetiracetam has no clinically relevant effect on painful polyneuropathy. Copyright (c) 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.

more studies >>

Clinical Trials Related to Keppra XR (Levetiracetam)

Conversion to Monotherapy Study With Keppra XR for Partial Seizures [Completed]
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures [Completed]
This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a history of seizures can be involved. The patient must present to the emergency department within 4 hours of a seizure. The purpose of this study is to compare these three drugs, phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs can prevent another seizure in the next 24 hours. We are also looking for any possible side effects.

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures [Completed]
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.

Keppra for Cervical Dystonia [Suspended]
The purpose of this study is to evaluate if there is an improved response in CD symptoms when Keppra is used as adjunctive therapy to Botox.

Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients [Completed]
Prospective randomized double blind controlled trial in prevention of relapse in recently detoxified alcohol dependent patients with levetiracetam and placebo.

more trials >>

Reports of Suspected Keppra XR (Levetiracetam) Side Effects

Convulsion (23)Foetal Exposure During Pregnancy (19)Pregnancy (16)Upper Respiratory Tract Infection (10)Premature Baby (10)Death (6)Dyspepsia (6)Inappropriate Schedule of Drug Administration (6)Rash (6)Cerebrovascular Accident (6)more >>

Page last updated: 2017-08-17

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017